Home Other Building Blocks 290815-26-8
290815-26-8,MFCD23843806
Catalog No.:AA002X62

290815-26-8 | Avosentan

Pack Size
Purity
Availability
Price(USD)
Quantity
  
5mg
≥98%
in stock  
$290.00   $203.00
- +
10mg
≥98%
in stock  
$375.00   $263.00
- +
50mg
≥98%
in stock  
$1,541.00   $1,079.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA002X62
Chemical Name:
Avosentan
CAS Number:
290815-26-8
Molecular Formula:
C23H21N5O5S
Molecular Weight:
479.5083
MDL Number:
MFCD23843806
SMILES:
COc1nc(nc(c1Oc1ccccc1OC)NS(=O)(=O)c1ccc(cn1)C)c1ccncc1
Properties
Computed Properties
 
Complexity:
732  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
34  
Hydrogen Bond Acceptor Count:
10  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
8  
XLogP3:
3.1  

Literature

Title: 2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials.

Journal: Minerva medica 20120801

Title: Antidiuretic effects of the endothelin receptor antagonist avosentan.

Journal: Frontiers in physiology 20120101

Title: Effect of avosentan (SPP-301) in porcine ciliary arteries.

Journal: Current eye research 20110201

Title: Effect of SPP 301, an endothelin antagonist, on intraocular pressure in glaucomatous monkey eyes.

Journal: Current eye research 20110101

Title: Diabetic nephropathy - Epidemiology in Asia and the current state of treatment.

Journal: Indian journal of nephrology 20110101

Title: Endothelin receptor blockade in patients with diabetic nephropathy.

Journal: Contributions to nephrology 20110101

Title: TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats.

Journal: International journal of hypertension 20110101

Title: Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse.

Journal: Diabetes 20101201

Title: Potential new therapeutic agents for diabetic kidney disease.

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation 20100501

Title: Avosentan for overt diabetic nephropathy.

Journal: Journal of the American Society of Nephrology : JASN 20100301

Title: The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice.

Journal: Diabetologia 20100101

Title: Channels and transporters. Mini-symposium of the Division of Medicinal Chemistry (DMC) of the Swiss Chemical Society (SCS) at the Department of Chemistry, University of Basel, May 27, 2010.

Journal: Chimia 20100101

Title: Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.

Journal: American journal of physiology. Renal physiology 20091101

Title: Absolute bioavailability and pharmacokinetics of avosentan in man.

Journal: International journal of clinical pharmacology and therapeutics 20090901

Title: Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects.

Journal: Clinical pharmacology and therapeutics 20090601

Title: Avosentan reduces albumin excretion in diabetics with macroalbuminuria.

Journal: Journal of the American Society of Nephrology : JASN 20090301

Title: Influence of food intake on the pharmacokinetics of avosentan in man.

Journal: International journal of clinical pharmacology and therapeutics 20080901

Title: Influence of avosentan (SPP3OI) on the pharmacokinetics of a second generation oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.

Journal: International journal of clinical pharmacology and therapeutics 20061201

Title: Pharmacokinetic interaction between ketoconazole and SPP301 in healthy volunteers.

Journal: International journal of clinical pharmacology and therapeutics 20060701

Title: Profile of past and current clinical trials involving endothelin receptor antagonists: the novel '-sentan' class of drug.

Journal: Experimental biology and medicine (Maywood, N.J.) 20060601

Title: Baltatu OC, Iliescu R, Zaugg CE, Reckelhoff JF, Louie P, Schumacher C, Campos LA.Antidiuretic effects of the endothelin receptor antagonist avosentan.Front Physiol. 2012;3:103.

Title: Konieczka K, Meyer P, Schoetzau A, Neutzner A, Mozaffarieh M, Flammer J.Effect of avosentan (SPP-301) in porcine ciliary arteries.Curr Eye Res. 2011 Feb;36(2):118-24.

Title: Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G; ASCEND Study Group.J Am Soc Nephrol. 2010 Mar;21(3):527-35.

Title: Dieterle W, Hengelage T.Absolute bioavailability and pharmacokinetics of avosentan in man.Int J Clin Pharmacol Ther. 2009 Sep;47(9):587-94.

Title: Effect of SPP 301, an Endothelin Antagonist, on Intraocular Pressure in Glaucomatous Monkey Eyes By Wang, Rong-Fang; Podos, Steven M.; Serle, Janet B.; Baltatu, Ovidiu C. From Current Eye Research (2011), 36(1), 41-46.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 290815-26-8
Tags:290815-26-8 Molecular Formula|290815-26-8 MDL|290815-26-8 SMILES|290815-26-8 Avosentan |Organic_Building_Blocks